Hypoxia-inducible factor 2 inhibitors show promise in advanced kidney cancer
NATURE REVIEWS UROLOGY（2021）
摘要
new phase I clinical trial has demonstrated that belzutifan provides a route to sustained inhibition of hypoxia-inducible factor 2α in humans that is well tolerated and could be useful in the treatment of advanced clear cell kidney cancer.
更多查看译文
关键词
Renal cell carcinoma,Targeted therapies,Medicine/Public Health,general,Urology
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要